[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-366450-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-366450-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","circulating-micrornas-as-biomarker-in-prostate-cancer-and-their-significance-in-the-differentiation-of-benign-and-malignant-conditions-of-the-prostate","Circulating microRNAs as biomarker in prostate cancer and their significance in the differentiation of benign and malignant conditions of the prostate","","Prostate cancer is among the most commonly diagnosed malignancies in men, and prostate-specific antigen (PSA) remains a widely used screening marker while lacking sufficient diagnostic accuracy due to false positives from benign conditions. This study profiles circulating microRNAs to identify a cancer-specific signature and assess its ability to distinguish localized and metastatic disease from benign prostatic hyperplasia. Using NanoString Human MicroRNA Arrays on serum from three patient groups, the work reports distinct up- and down-regulated miRNAs and evaluates their potential for early diagnosis, risk stratification, non-invasive monitoring, and reducing unnecessary biopsies. Validation in larger independent cohorts is required due to cost, technical complexity, and lack of standardization.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/circulating-micrornas-as-biomarker-in-prostate-cancer-and-their-significance-in-the-differentiation-of-benign-and-malignant-conditions-of-the-prostate/366450/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/circulating-micrornas-as-biomarker-in-prostate-cancer-and-their-significance-in-the-differentiation-of-benign-and-malignant-conditions-of-the-prostate/366450.png","ImageObject",300,407,{"name":42,"@type":43},"Grenda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are circulating microRNAs being investigated for prostate cancer biomarkers?","Question",{"text":63,"@type":64},"PSA screening lacks sufficient specificity because its levels can rise due to benign prostatic hyperplasia and other nonmalignant conditions. Circulating microRNAs are stable, noncoding regulators detectable in serum and other fluids, making them promising for noninvasive biomarkers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were circulating microRNAs analyzed in this study?",{"text":68,"@type":64},"The study used NanoString Human MicroRNA Arrays to analyze serum samples from three groups: localized prostate cancer, metastatic prostate cancer, and benign prostatic hyperplasia.",{"name":70,"@type":61,"acceptedAnswer":71},"Which microRNAs showed significant differential expression between prostate cancer and BPH?",{"text":72,"@type":64},"MiR-1272 and miR-1247-5p were significantly up-regulated, while miR-337-3p, miR-191-5p, and let-7a-5p were significantly down-regulated in prostate cancer versus BPH. The study also found notable differences when comparing localized versus metastatic disease.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},366450,1790418763,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971474921005,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","| Original Article |  |\n| --- | --- |\n|  |  |\n| Circulating microRNAs as biomarker in prostate cancer and their significance in the differentiation of benign and malignant conditions of the prostate\u003Cbr>Kowsalya Ramprasad, Madhura Navule Siddappa, Manohar Chikkamoga Siddaiah1, Manju Moorthy2, Gopalakrishna Ramaswamy2\u003Cbr>Departments of Biochemistry and 1Urology, Institute of Nephrourology, 2 Department of Bioinformatics, Theracues Innovations Private Limited, Bengaluru, Karnataka, India |  |\n|  |  |\n| Abstract \u003Cbr>Background: Prostate cancer is among the most commonly diagnosed cancers in males worldwide. While Prostate-specific antigen (PSA) remains the front-line screening marker, it lacks sufficient diagnostic accuracy. Aims and Objectives: So, in the quest for improved biomarkers, the expression profiles of circulating miRNAs have become increasingly significant. Hence, this study was undertaken to identify the miRNA profile unique to prostate cancer.\u003Cbr>Materials and Methods: Using NanoString Human MicroRNA Arrays, we analyzed serum samples from three groups: patients with localized prostate cancer, metastatic prostate cancer, and benign prostatic hyperplasia. Results: Our analysis revealed distinct circulating miRNA expression patterns in prostate cancer patients compared to those with benign conditions. Specifically, miR-1272 and miR-1247-5p were significantly up-regulated (log2FC > 1, p \u003C 0.05), whereas miR-337-3p, miR-191-5p, and let-7a-5p were significantly down-regulated (log2FC \u003C -1, p \u003C 0.05) in prostate cancer versus BPH. Additionally, when comparing localized and metastatic prostate cancer, hsa-miR-302d-3p and hsa-miR-1246 were notably up-regulated (log2FC > 3, P \u003C 0.05) . These specific miRNAs show potential for facilitating early diagnosis, enhancing risk stratification, and serving as non-invasive biomarkers for monitoring disease progression, thereby helping to reduce the need for unnecessary biopsies.\u003Cbr>Conclusions: Our findings suggest that circulating miRNAs could serve as minimally invasive biomarkers in prostatic cancer with a higher specificity and sensitivity, making them more effective at distinguishing between cancerous and benign conditions. However, despite their promise, miRNA testing remains costly, technically complex, and not yet standardized for routine clinical use. Therefore, further validation in larger, independent cohorts is essential to confirm the diagnostic and prognostic utility ofthe miRNAs identified in this study.\u003Cbr>Keywords: Benign, biomarker, cancer, metastasis, miRNAs, nanostring, prostate |  |\n| Address for correspondence: Dr. Kowsalya Ramprasad, Department of Biochemistry, Institute of Nephrourology, Victoria Hospital Campus, Bengaluru-560 002, Karnataka, India.\u003Cbr>E-mail: [r.kowsalya@gmail.com](r.kowsalya@gmail.com)\u003Cbr>Received: 13.01. 2025, Revised: 05.05. 2025, Accepted: 20.05. 2025, Published: 18.07.2025. |  |\n\n\n| Access this article online |  |\n| --- | --- |\n| Quick Response Code: | Website:\u003Cbr>[https://journals.lww.com/UROL/](https://journals.lww.com/UROL/) |\n| |  |\n|  | DOI:\u003Cbr>10.4103/ua. ua_11_25 |\n\n192 © 2025 Urology Annals | Published by Wolters Kluwer-Medknow  \nRamprasad, et al.: Circulating miRNA and prostate cancer  \nINTRODUCTION  \nProstate cancer (PC) is the second most commonly diagnosed malignancy and a leading cause of cancer‑related death among men worldwide. The global incidence currently stands at 31.1 per 100,000 population, accounting for approximately 15% of all cancer cases. [1] In 2022, an estimated 1,467,854 new cases of PC were diagnosed, resulting in 397,430 deaths globally.[2] Despite advancesin treatment, prognosis remains poor for patients with metastatic disease, with only 28% surviving beyond 5 years. Despite all medical advancements, PC remains a major cause of mortality in men worldwide. [3]  \nThe widespread adoption of prostate‑specific antigen (PSA) testing in the early 1990s significantly increased the detection of PC. However, PSA lacks","cbCaivFbUdROExeh","https://ap.wps.com/l/cbCaivFbUdROExeh","pdf",11147362,15,"English","# Abstract\n## Background and Aims and Objectives\n## Materials and Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"Why are circulating microRNAs being investigated for prostate cancer biomarkers?\",\"answer\":\"PSA screening lacks sufficient specificity because its levels can rise due to benign prostatic hyperplasia and other nonmalignant conditions. Circulating microRNAs are stable, noncoding regulators detectable in serum and other fluids, making them promising for noninvasive biomarkers.\"},{\"question\":\"How were circulating microRNAs analyzed in this study?\",\"answer\":\"The study used NanoString Human MicroRNA Arrays to analyze serum samples from three groups: localized prostate cancer, metastatic prostate cancer, and benign prostatic hyperplasia.\"},{\"question\":\"Which microRNAs showed significant differential expression between prostate cancer and BPH?\",\"answer\":\"MiR-1272 and miR-1247-5p were significantly up-regulated, while miR-337-3p, miR-191-5p, and let-7a-5p were significantly down-regulated in prostate cancer versus BPH. The study also found notable differences when comparing localized versus metastatic disease.\"}]","Circulating microRNAs as biomarker in prostate cancer and their significance in the differentiation of benign and malignant conditions of the prostate | PDF",1790165636,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1177318cb4f139309a07565fc3075199.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aee8de0a0c41eded77bb8f27977c03df.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/728b55fd981e9095d5078bfeb13a1200.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc8a309cf23310e6657adda2c582e588.webp",980,1268]